News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Mark Lythgoe: Subcutaneous nivolumab approved by FDA Oncology across all indications
Dec 31, 2024, 09:49

Mark Lythgoe: Subcutaneous nivolumab approved by FDA Oncology across all indications

Mark Lythgoe, Clinical Research Fellow in Medical Oncology at Imperial College London, shared on X:

“Subcutaneous nivolumab approved by FDA Oncology across all indications – follows approval of SC atezolizumab in September 2024.

Will this be the preferred route of administration or will this suppress the development of new biosimilars?”

The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations

Authors: Matthew J. Hadfield1, David J. Benjamin, Jonathan Krell, Jeremy Warner, Mark P. Lythgoe

Mark Lythgoe

atezolizumab biosimilars cancer FDA Mark Lythgoe nivolumab OncoDaily Oncology
Special Coverage
Insight
Dec 31, 2024, 09:49
Mark Lythgoe: Subcutaneous nivolumab approved by FDA Oncology across all indications
Insight
Dec 31, 2024, 09:45
Andrea Boutros: Neoadjuvant therapy is likely to become the standard for stage III Melanoma Treatment
Insight
Dec 31, 2024, 09:39
NFCR joins the nation in mourning the passing of former President James (Jimmy) Carter
Science
Dec 31, 2024, 09:36
Mutational signature-based classification of ampullary carcinoma
Blog
Dec 31, 2024, 08:53
Carmen Uscatu: What do you promise for 2025?
Blog
Dec 31, 2024, 08:41
Luchuo Engelbert Bain: Conceptualizing, Measuring and Scaling Impact in Global Health Research
Blog
Dec 31, 2024, 08:33
Cynthia Jordan: Your mammogram, take it seriously, ask questions and know more than I did
Science
Dec 31, 2024, 08:26
Adebayo Falola: Outcomes of the robotic approach with laparoscopy for the management of CRC in Africa
Science
Dec 31, 2024, 08:07
Aman Chauhan: Exciting collaborations
Blog
Dec 31, 2024, 08:01
David Velasquez: We must do better for our seniors
Blog
Dec 31, 2024, 07:46
Emad Shash: Reflection on 2024 - A Year of Growth, Achievements and Resilience
Science
Dec 31, 2024, 07:29
Gustavo Viani: How has the treatment landscape for CNS primary lymphoma evolved over decades?